Inovio Pharmaceuticals
125 hedge funds and large institutions have $143M invested in Inovio Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 39 increasing their positions, 27 reducing their positions, and 23 closing their positions.
137% more call options, than puts
Call options by funds: $705K | Put options by funds: $298K
44% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 27
0.13% more ownership
Funds ownership: 2.98% → 3.11% (+0.13%)
4% less funds holding
Funds holding: 130 → 125 (-5)
17% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 23
22% less capital invested
Capital invested by funds: $182M → $143M (-$39.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$3.02M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$2.89M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.54M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.5M |
| 5 |
BlackRock
New York
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.22M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.86M |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$482K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$440K |
| 5 |
Morgan Stanley
New York
|
-$361K |
INO Hedge Fund Activity: Q4 2018 in Review
125 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q4 2018, worth a combined $143M — down 22% from $182M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of INO and 19 opened new positions — a net loss of 4 holders — while 27 trimmed existing stakes and 39 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $3.02M. The largest seller was Fidelity Investments, exiting entirely with an estimated $2.22M sold.
- 125 institutional investors held Inovio Pharmaceuticals (INO) as of Q4 2018, down from 130 in Q3 2018.
- Funds reported $143M of Inovio Pharmaceuticals stock for Q4 2018, down 22% quarter-over-quarter.
- 19 funds opened new Inovio Pharmaceuticals positions in Q4 2018 and 23 closed out, a net change of -4 holders.
- The largest Inovio Pharmaceuticals buyer in Q4 2018 was D.E. Shaw & Co, an estimated $3.02M added.
- The largest Inovio Pharmaceuticals seller in Q4 2018 was Fidelity Investments, an estimated $2.22M sold.
Based on aggregated 13F filings for Q4 2018.